Compare ZKIN & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | RANI |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 84.6M |
| IPO Year | 2017 | 2021 |
| Metric | ZKIN | RANI |
|---|---|---|
| Price | $1.70 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 54.8K | ★ 558.1K |
| Earning Date | 08-21-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $283.19 |
| Revenue Next Year | N/A | $5.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $1.00 | $0.61 |
| 52 Week High | $3.11 | $3.87 |
| Indicator | ZKIN | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 34.76 |
| Support Level | $1.30 | $0.61 |
| Resistance Level | $1.94 | $0.85 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.81 | 18.05 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.